SCHEMBL3480255

SCHEMBL3480255

COc1cc2ccsc2cc1OC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.48
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
CTNNB1 P35222 1/20 0.42
WNT3A P56704 1/20 0.42
ALDH1A1 P00352 1/20 0.41
RPS6KB2 Q9UBS0 2/20 0.41
PDGFRB P09619 3/20 0.40
PDGFRA P16234 3/20 0.40
KEAP1 Q14145 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
CYP2A6 P11509 2/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
NQO2 P16083 1/20 0.38
MCL1 Q07820 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29703102 1.00 PDE10A (0.48) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL28745023 0.94 PDE10A (0.45) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL7321426 0.86 STING1 (0.46) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL10370267 0.86 MAPT (0.46) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL5212359 0.86 HDAC8 (0.44) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL16492196 0.84 HTR2A (0.44) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL20557882 0.84 HTR2A (0.44) PDE10AMAPTCTNNB1WNT3AALDH1A1
SCHEMBL29976585 0.84 HTR2A (0.44) PDE10AMAPTTSHRCTNNB1WNT3A
SCHEMBL10367797 0.84 GAA (0.42) PDE10AMAPTCTNNB1WNT3AALDH1A1
SCHEMBL19756674 0.84 RAB9A (0.40) PDE10AMAPTTSHRCTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312324-B2 Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-05-27 US disclosed
CN-114605378-B Thiophene condensed ring compound and synthetic method and application thereof 华中科技大学 2023-11-14 CN disclosed
WO-2023005267-A1 BENZO [B] SELENOPHENE STING REGULATING AGENT, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 中国药科大学 2023-02-02 WO disclosed
CN-111393405-B Fluorine-containing substituted benzothiophene compounds, and pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-11-25 CN disclosed
CN-114605378-A Thiophene condensed ring compound and synthesis method and application thereof 华中科技大学 2022-06-10 CN disclosed
US-20220089561-A1 FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2022-03-24 US disclosed
CN-110036001-B Benzo [ b ] thiophene compounds as STING agonists 默沙东公司 2022-03-22 CN disclosed
WO-2022002077-A1 ARYL AROMATIC HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海海和药物研究开发股份有限公司 2022-01-06 WO disclosed
EP-3907221-A1 FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-11-10 EP disclosed
EP-3907221-A1 FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-11-10 EP disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 EP disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 WO disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed
US-6946462-B2 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2005-09-20 US disclosed
US-6869953-B2 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents HOFFMAN-LA ROCHE INC. (US) 2005-03-22 US disclosed
EP-0129478-B1 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE MERCK & CO. INC. (US) 1990-01-17 EP disclosed
US-4788192-A TOPICALLY APPLYING; FOR GLAUCOMA MERCK & CO., INC. (US) 1988-11-29 US disclosed
US-4668697-A Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor MERCK & CO., INC. (US) 1987-05-26 US disclosed
EP-0129478-A2 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1984-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089561-A1 FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF FLI1, ABCG2, AFF1 PDE10A 2168/4885MAPT 503/4885TSHR 1680/4885
US-12312324-B2 Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof FLI1, ABCG2, AFF1 PDE10A 2168/4885MAPT 503/4885TSHR 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.